Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $200000.0.

  • Taysha Gene Therapies' Depreciation & Amortization (CF) fell 3333.33% to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1636.36%. This contributed to the annual value of $1.2 million for FY2024, which is 1107.14% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Depreciation & Amortization (CF) is $200000.0, which was down 3333.33% from $300000.0 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Depreciation & Amortization (CF) registered a high of $400000.0 during Q2 2023, and its lowest value of $200000.0 during Q3 2025.
  • Moreover, its 4-year median value for Depreciation & Amortization (CF) was $300000.0 (2022), whereas its average is $316333.3.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 3333.33% in 2023, then tumbled by 3333.33% in 2025.
  • Over the past 4 years, Taysha Gene Therapies' Depreciation & Amortization (CF) (Quarter) stood at $390000.0 in 2022, then increased by 1.28% to $395000.0 in 2023, then fell by 23.04% to $304000.0 in 2024, then plummeted by 34.21% to $200000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $200000.0 in Q3 2025, compared to $300000.0 in Q2 2025 and $300000.0 in Q1 2025.